Skip to Main Content

Paper Details

Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Clin Cancer Res
6
2023
ATR, ATRi, BRCA1/2, BRCA1/2 mutations, CA-125, HGSOC, HGSOC) cell, HGSOCs, HR, Homologous Recombination-Deficient Ovarian Cancer, PARP, PARPi, PARPi-resistant HGSOCs, Patients, Rad3-related kinase, anemia, ataxia telangiectasia, carboplatin, ceralasertib, high-grade serous ovarian cancer, mouse, neutropenia, olaparib, paclitaxel, patient, patients, platinum, thrombocytopenia, tumors
Author NameAffiliation
Susan M DomchekBasser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania
Susan M DomchekAbramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Susan M DomchekPerelman School of Medicine at the University of Pennsylvania
Ronny DrapkinBasser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania
Ronny DrapkinAbramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Ronny DrapkinPerelman School of Medicine at the University of Pennsylvania
Ronny DrapkinBasser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania
Ronny DrapkinAbramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Ronny DrapkinPerelman School of Medicine at the University of Pennsylvania
  • 1 - 9

Datasets

Release 1.2